AR039917A1 - Compuesto de pirrol, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento - Google Patents

Compuesto de pirrol, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento

Info

Publication number
AR039917A1
AR039917A1 ARP030101905A ARP030101905A AR039917A1 AR 039917 A1 AR039917 A1 AR 039917A1 AR P030101905 A ARP030101905 A AR P030101905A AR P030101905 A ARP030101905 A AR P030101905A AR 039917 A1 AR039917 A1 AR 039917A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
aryl
represents hydrogen
heteroaryl
Prior art date
Application number
ARP030101905A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR039917A1 publication Critical patent/AR039917A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Un compuesto de pirrol que tiene la fórmula (1), en la que: A representa un grupo arilo opcionalmente sustituido, o un anillo de heterociclilo de 5 o 6 miembros, opcionalmente sustituido, o un grupo heterociclilo bicíclico opcionalmente sustituido; R1 representa CO2H, CN, CONR5R6, CH2CO2H, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, SO2alquilo opcionalmente sustituido, SO2NR5R6, NR5CONR5R6, COalquilo, 2H-tetrazol-5-il-metilo, heterociclo bicíclico opcionalmente sustituido o heterociclilo opcionalmente sustituido; R2a y R2b independientemente representan hidrógeno, halo, alquilo opcionalmente sustituido, alcoxi opcionalmente sustituido, CN, SO2alquilo, SR5, NO2, arilo opcionalmente sustituido, CONR5R6 o heteroarilo opcionalmente sustituido; Rx representa alquilo opcionalmente sustituido en donde 1 o 2 de los átomos de carbono no terminales pueden estar opcionalmente reemplazados por un grupo seleccionado independientemente de NR4, O y SOn en donde n es 0, 1 o 2; o Rx puede ser CQ2-heterociclilo opcionalmente sustituido, CQ2-heterociclilo bicíclico opcionalmente sustituido o CQ2-arilo opcionalmente sustituido; R4 representa hidrógeno o un alquilo opcionalmente sustituido; R5 representa hidrógeno o un alquilo opcionalmente sustituido; R6 representa hidrógeno o alquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, SO2-arilo opcionalmente sustituido, SO2-alquilo opcionalmente sustituido, SO2-heteroarilo opcionalmente sustituido, CN, CQ2-arilo opcionalmente sustituido, CQ2-heteroarilo opcionalmente sustituido o COR7; R7 representa hidrógeno, alquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o arilo opcionalmente sustituido; R8 representa hidrógeno, CF3, o alquilo; R9 representa hidrógeno, CF3, o alquilo; Q se selecciona independientemente de hidrógeno y CH3; en donde cuando A es un anillo de 6 miembros, el sustituyente R1 y el anillo de pirrol están unidos a los átomos de carbono 1,2-, 1,3- o 1,4- uno respecto del otro y, cuando A es un anillo de cinco miembros o un grupo heterociclilo bicíclico, el sustituyente R1 y el anillo de pirrol están unidos a los átomos de carbono sustituibles 1,2- o 1,3- uno respecto del otro; o uno de sus derivados. Composiciones farmacéuticas que comprenden tales compuestos y el uso de los mismos para preparar medicamentos de aplicación en el tratamiento de una enfermedad que está mediada por la acción de PGE2 en los receptores EP1.
ARP030101905A 2002-05-31 2003-05-29 Compuesto de pirrol, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento AR039917A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0212785.0A GB0212785D0 (en) 2002-05-31 2002-05-31 Compounds

Publications (1)

Publication Number Publication Date
AR039917A1 true AR039917A1 (es) 2005-03-09

Family

ID=9937924

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101905A AR039917A1 (es) 2002-05-31 2003-05-29 Compuesto de pirrol, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento

Country Status (8)

Country Link
US (1) US20070082912A1 (es)
EP (1) EP1509499A1 (es)
JP (1) JP2005532347A (es)
AR (1) AR039917A1 (es)
AU (1) AU2003238455A1 (es)
GB (1) GB0212785D0 (es)
TW (1) TW200404775A (es)
WO (1) WO2003101959A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0306329D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Compounds
GB0323585D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
DE602004011966T2 (de) * 2003-10-24 2009-02-12 Glaxo Group Ltd., Greenford Heterocyclylverbindungen
GB0328024D0 (en) * 2003-12-03 2004-01-07 Glaxo Group Ltd Compounds
WO2006066968A1 (en) 2004-12-23 2006-06-29 Glaxo Group Limited Pyridine compounds for the treatment of prostaglandin mediated diseases
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
EP1893612B1 (en) * 2005-06-22 2011-08-03 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
CA2677769C (en) 2007-02-16 2016-01-19 Ono Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder
EP2314587A4 (en) * 2008-07-17 2012-01-25 Asahi Kasei Pharma Corp HETEROCYCLIC NITROGEN COMPOUND
DK2315590T3 (da) * 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
EP2318007B1 (en) 2008-08-15 2013-01-23 N30 Pharmaceuticals, Inc. Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
EP3069721A1 (en) 2008-08-15 2016-09-21 Nivalis Therapeutics, Inc. Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
KR20110116161A (ko) 2009-01-19 2011-10-25 아보트 러보러터리즈 암, 면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
CN102574778B (zh) * 2009-06-22 2015-01-07 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
EP2570125A1 (en) * 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands
US9012450B2 (en) 2011-12-28 2015-04-21 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
CN104135859B (zh) 2011-12-28 2017-06-27 全球血液疗法公司 取代的苯甲醛化合物及其用于增加组织氧合的方法
RS59394B1 (sr) * 2012-09-07 2019-11-29 Boehringer Ingelheim Int Alkoksi pirazoli kao rastvorljivi aktivatori guanilatne ciklaze
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008721A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
MY183637A (en) 2013-03-15 2021-03-04 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PT3102208T (pt) 2014-02-07 2021-04-05 Global Blood Therapeutics Inc Polimorfos cristalinos da base livre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3 il)metoxi)benzaldeído
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
PL3436446T3 (pl) 2016-03-31 2023-09-11 Vertex Pharmaceuticals Incorporated Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
DK3551622T3 (da) 2016-12-09 2020-11-23 Vertex Pharma Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AR112467A1 (es) 2017-08-02 2019-10-30 Vertex Pharma Procesos para preparar compuestos
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US11014884B2 (en) 2018-10-01 2021-05-25 Global Blood Therapeutics, Inc. Modulators of hemoglobin
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
JP2023519605A (ja) 2020-03-31 2023-05-11 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
EP0946507B1 (en) * 1996-12-10 2003-09-24 G.D. SEARLE & CO. Substituted pyrrolyl compounds for the treatment of inflammation
EP1216238B1 (en) * 1999-09-14 2004-02-18 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
EP1284260A4 (en) * 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd TYROSINE PHOSPHATASE INHIBITORS

Also Published As

Publication number Publication date
US20070082912A1 (en) 2007-04-12
GB0212785D0 (en) 2002-07-10
TW200404775A (en) 2004-04-01
JP2005532347A (ja) 2005-10-27
AU2003238455A1 (en) 2003-12-19
EP1509499A1 (en) 2005-03-02
WO2003101959A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
AR039917A1 (es) Compuesto de pirrol, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
AR041875A1 (es) Compuesto de fenilo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento y procedimiento para preparar dicho compuesto
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
AR038818A1 (es) Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR058338A1 (es) Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa.
CY1105035T1 (el) Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
PA8547701A1 (es) Nucleosidos 4 substituidos.
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AR054863A1 (es) DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA
AR031613A1 (es) Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
CY1107703T1 (el) Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης
AR074632A1 (es) Compuesto de amidofenoxiindazol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util en el tratamiento de cancer
AR055554A1 (es) Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos
PE20040655A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
PA8582801A1 (es) Nuevos derivados espirotricíclicos y su uso como inhibidores de la fosfodiesterasa
AR041395A1 (es) Compuesto de piridina composicion farmaceutica que lo comprende y su uso para prepararla
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
TR200402454T4 (tr) C-4 karbonat taksanlar.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal